Hypothesis

Morning light exposure advances the phosphorylation state of PER2 in the suprachiasmatic nucleus, which in turn alters the sensitivity of the ipRGC‑SCN‑adrenal axis to evening blue light, resulting in a genotype‑dependent modulation of melatonin suppression and downstream metabolic outcomes.

Mechanistic Rationale

Morning photons activate melanopsin in ipRGCs, driving glutamate release that shifts the core clock by promoting PER2 phosphorylation via CK1δ/ε. This phase advance changes the temporal window during which glucocorticoid signaling from the adrenal gland peaks. Altered glucocorticoid timing modulates hepatic PER2 expression and influences the amplitude of the evening melatonin response to blue‑light‑driven ipRGC activation. Individuals carrying the OPN4 P10L polymorphism exhibit reduced melanopsin sensitivity, leading to a blunted phase advance after morning light and a heightened melatonin suppression response to evening blue light.

Predictions & Experimental Design

1. Participants stratified by OPN4 genotype (wild‑type vs P10L) will receive a standardized 30‑minute 250‑lux 480‑nm light pulse at 07:00 h for three consecutive days.
2. Following the morning intervention, dim light melatonin onset (DLMO) will be measured each evening to quantify phase advance.
3. On the fourth evening, participants will be exposed to a 2‑hour blue‑light enrichment (460 nm, 30 μW/cm²) from 20:00–22:00 h while salivary melatonin and cortisol are sampled every 20 min.
4. We predict that wild‑type subjects will show a ≥2‑hour DLMO advance after morning light and a ≤30 % melatonin suppression during the evening blue‑light block, whereas P10L carriers will exhibit <1‑hour DLMO advance and ≥50 % melatonin suppression.
5. Parallel peripheral blood mononuclear cell assays will assess PER2 phosphorylation status (phospho‑specific Western blot) and hepatic gluconeogenic gene expression (G6PC, PCK1) to link central phase shifts to metabolic readouts.

Potential Implications

If confirmed, this hypothesis would explain interindividual variability in chronotherapy efficacy and support personalized lighting prescriptions that weigh both morning advance stimulus and evening blue‑light exposure based on OPN4 genotype. It also suggests that timed morning light could be used to 'reset' the ipRGC‑SCN‑adrenal coupling, reducing metabolic risk in shift‑free populations exposed to artificial lighting at night.